Description: ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Home Page: www.alteogen.com
62, Yuseong-daero
Daejeon,
34054
South Korea
Phone:
82 4 2384 8780
Officers
| Name | Title |
|---|---|
| Dr. Soon-Jae Park Ph.D. | Chief Exec. Officer |
| Mr. Hang Yeon Kim | CFO & Exec. VP |
| Mr. Seung Joo Lee | CTO, Exec. VP and Head of R&D Center |
| Dr. Hye-Shin Chung Ph.D. | Chief Scientific Officer |
| Ms. Sang-Mee Lee | VP & Head of Research Planning |
| Mr. Sang Woo Kang | Sr. VP of Management Support Group |
| Dr. Tae-Yon Chun J.D., Ph.D. | Sr. VP & Corp. Alliance Officer (CAO) |
| Mr. Kyuwan Kim | Sr. VP & Head of New Drug Devel. |
| Mr. Vivek B Shenoy M.B.A., Ph.D. | Chief Bus. Devel. Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 15.106 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |